Context Therapeutics Inc. (CNTX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
2001 Market Street
Philadelphia, PA 19103
United States of America (the)
Phone
267 225 7416
Sector
Healthcare
Industry
Biotechnology
Employees
12
First IPO Date
October 20, 2021
| Name | Title | Pay | Year Born |
| Martin A. Lehr | Co-Founder, President, Chief Executive Officer & Director | 914,015 | 1984 |
| Karen Chagin | Chief Medical Officer | 26,610 | 1977 |
| Alex C. Levit | Chief Legal Officer & Corporate Secretary | 576,307 | 1979 |
| Jennifer Minai-Azary | Chief Financial Officer & Treasurer | 610,731 | 1978 |
| Christopher Beck | Senior Vice President of Operations | 0 | N/A |
| Jeffrey Liebman | Associate Director of Accounting | 0 | N/A |
| Jennifer Dashnau | Senior Vice President of Technical Operations | 0 | N/A |
Context Therapeutics Inc. (CNTX) is a biopharmaceutical firm in the clinical development stage, dedicated to advancing cancer treatments specifically for women in the United States. Its leading investigational therapy is onapristone extended release (ONA-XR). This compound functions as a potent and selective antagonist of the progesterone receptor, aiming to counteract the resistance often encountered with various cancer therapeutics, particularly anti-estrogen therapies, in hormone-dependent female cancers. The company is also progressing with CLDN6xCD3 bsAb, a bispecific monoclonal antibody designed to target both CD3 and Claudin 6 antigens. Its mechanism involves redirecting T-cell-mediated destruction towards malignant cells that express CLDN6. Furthermore, Context Therapeutics Inc. holds a collaboration and licensing agreement with Integral Molecular, Inc. This partnership focuses on the development of an anti-claudin 6 bispecific monoclonal antibody for the treatment of gynecologic cancers. Established in 2015, Context Therapeutics Inc. operates out of its headquarters in Philadelphia, Pennsylvania.